Capillary Technologies India Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Capillary Technologies India Ltd trades at ₹492, in a downtrend and 21 weeks into that stage. That is −11.5% against its own 200-day average. It sits at 0% of a 52-week range of ₹492 to ₹719. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (12 weeks and counting).

Today the stock is in a downtrend — week 21 of stage 4, confirmed. At ₹492 it trades −11.5% versus its 200-day average and sits at 0% of its 52-week range (₹492–₹719).

Against the market, two honest reads. Cumulative: over the last 8 months the stock moved −19% while the NIFTY 500 moved −3% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (12 weeks and counting; last ahead the week of 2026-05-29) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 1st percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Capillary Technologies India Ltd trades at 128.0× P/E, about the cheapest it has ever traded. Its long-run median P/E is 268.7×, measured across 0.7 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 128.0× is about the cheapest it has ever traded, against a long-run median of 268.7× measured over 0.7 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Capillary Technologies India Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 4 quarters across 1 curve, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

The latest quarter’s profit carries a one-off item larger than the operating base, so the profit curve is shown but does not vote in the stage call.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

49.6/100 — rank 32 of 63 in IT - Software · 59% evidence confidence

Capillary Technologies India Ltd scores 49.6 out of 100 against the 63 companies it is compared with in IT - Software, ranking 32. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 21.6 + 9.3 + 8.7 + 10 = 49.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Capillary Technologies India Ltd reported ₹191 Cr of revenue in the Mar 26 quarter, +25.7% year on year. That is the 2nd straight quarter of year-on-year growth. Over 5 years it has compounded at 33.9% a year. The last full year, FY26, came in at ₹735 Cr. The last four reported quarters add to ₹706 Cr.

Capillary Technologies India Ltd reported ₹191 Cr of revenue in the Mar 26 quarter, +25.7% year on year. That is the 2nd straight quarter of year-on-year growth. Over 5 years it has compounded at 33.9% a year. The last full year, FY26, came in at ₹735 Cr. The last four reported quarters add to ₹706 Cr.

FY26 revenue came in at ₹735 Cr (+22.9% on the year), capping 5 years at 33.9% compound. The latest quarter (Mar 26) printed ₹191 Cr, +25.7% year on year — the 2nd consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +20.7% growth against the decade's 33.9% — the current year is running slower than its own long-run rate.

→ Revenue grew — did margins hold as it scaled? Next: 16.0% this quarter (−2.0 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Capillary Technologies India Ltd's operating margin is 16.0% in the Mar 26 quarter, −2.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across the last four quarters the operating margin has moved +2.0 percentage points.

Capillary Technologies India Ltd's operating margin is 16.0% in the Mar 26 quarter, −2.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across the last four quarters the operating margin has moved +2.0 percentage points.

The latest quarter's operating margin is 16.0%, −2.0 pp against the same quarter a year ago. Across 6 fiscal years the operating margin has ranged −23.0%–13.0%, and FY26's 13.0% is the top of that band — a record year.

Why the margin moved: operating margin went +2.0 pp year on year while gross margin went +0.0 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

→ Margins slipped — did that reach the bottom line? Next: profit +330.0% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Capillary Technologies India Ltd earned ₹43.0 Cr of net profit in the Mar 26 quarter, +330.0% year on year. Full-year FY26 profit was ₹52.0 Cr. That is 22.5% of the quarter's revenue. The same quarter a year earlier earned ₹10.0 Cr.

Capillary Technologies India Ltd earned ₹43.0 Cr of net profit in the Mar 26 quarter, +330.0% year on year. Full-year FY26 profit was ₹52.0 Cr. That is 22.5% of the quarter's revenue. The same quarter a year earlier earned ₹10.0 Cr.

Mar 26 profit was ₹43.0 Cr, +330.0% year on year. On the full year, FY26 printed ₹52.0 Cr (+300.0%).

→ Profit rose — but did the cash follow? Next: 160% of the last 2 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 2 fiscal years 160% of Capillary Technologies India Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹150 Cr of operating cash against ₹52.0 Cr of profit. After ₹240 Cr of capital spending, ₹−90.0 Cr was left as free cash.

FY26: operating cash of ₹150 Cr against reported profit of ₹52.0 Cr, leaving free cash of ₹−90.0 Cr after ₹240 Cr of capital spending. Across the last 2 fiscal years the conversion rate is 160% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 160%: the cash cycle tightened 27 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.

Router verdict: the bigger cash user is investment — capital spending ran 2.3× depreciation over three years, so the next section's job is to check what that build-out is buying.

→ So follow the cash to where it goes. Next: ₹442 Cr of building over 3 years.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Capillary Technologies India Ltd's cash conversion cycle runs 90 days in FY26, down from 117 days in FY21. Capital spending ran ₹442 Cr over the last 3 years. At FY26 sales of ₹735 Cr each day of that cycle holds about ₹2.0 Cr, so roughly ₹181 Cr sits inside the business at any moment.

FY26: debtors at 90 days (an asset-light business — no inventory to speak of) — for a full cycle of 90 days, tighter than FY21's 117.

In money terms: at FY26 sales of ₹735 Cr, each day of the cycle holds about ₹2.0 Cr — so the 90-day loop keeps roughly ₹181 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹442 Cr over the last 3 fiscal years against ₹191 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 4% and the ROIC − WACC spread is −9.7 pp.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Capillary Technologies India Ltd earns a ROCE of 4% in FY26. That is up from a trough of −68% in FY22. Return on invested capital clears the cost of that capital by −9.7 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 7.1% net margin on 0.57× asset turns.

FY26 ROCE is 4%, recovered from a FY22 trough of −68% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY26): 7.1% net margin × 0.57× asset turns × 1.27× balance-sheet leverage ≈ 5.1% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 2.3% − 12.0% = a −9.7 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.05.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Capillary Technologies India Ltd carries total debt of ₹54.0 Cr against shareholder equity of ₹1,023 Cr as of Mar 26, a debt-to-equity of 0.05 — effectively unlevered. On the annual view that ratio went from 0.19 in FY25 to 0.05 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹54.0 Cr against shareholder equity of ₹1,023 Cr — a debt-to-equity of 0.05. On the annual view, debt-to-equity went from 0.19 (FY25) to 0.05 (FY26). The returns on this page are earned, not borrowed.

→ Who owns this, and are they adding or leaving? Next: the register is quiet.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of Capillary Technologies India Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — .

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Capillary Technologies India Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions